ArticleTheranostics2015
A Prodrug-type, MMP-2-targeting Nanoprobe for Tumor Detection and Imaging.
Article in Theranostics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 74 citations in OpenAlex.
- CSF1R inhibitor C19 for glioma immunotherapy enabled by brain-targeting liposomal delivery.Acta pharmacologica Sinica · 2026Article
- Optical and Photoacoustic Imaging.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- Challenges and advances for glioma therapy based on inorganic nanoparticles.Materials today. Bio · 2023Review
- Enzyme-Responsive Double-Locked Photodynamic Molecular Beacon for Targeted Photodynamic Anticancer Therapy.Journal of the American Chemical Society · 2023Article
- Article
- Dual-targeting prodrug nanotheranostics for NIR-Ⅱ fluorescence imaging-guided photo-immunotherapy of glioblastoma.Acta pharmaceutica Sinica. B · 2022Article
- An activated excretion-retarded tumor imaging strategy towards metabolic organs.Bioactive materials · 2022Article
- Nanomaterial Technology and Soft Tissue Sarcomas.Frontiers in oncology · 2022Review
- Modular Design of Supramolecular Ionic Peptides with Cell-Selective Membrane Activity.Chembiochem : a European journal of chemical biology · 2021Article
- Targeted Delivery of a Matrix Metalloproteinases-2 Specific Inhibitor Using Multifunctional Nanogels to Attenuate Ischemic Skeletal Muscle Degeneration and Promote Revascularization.ACS applied materials & interfaces · 2021Article
- Towards extracellular matrix normalization for improved treatment of solid tumors.Theranostics · 2020Review
- Tumor gene therapy by systemic delivery of plasmid DNA with cell-penetrating peptides.FASEB bioAdvances · 2019Article
- Dual-targeting biomimetic delivery for anti-glioma activityChemical science · 2018Article
- HAase-sensitive dual-targeting irinotecan liposomes enhance the therapeutic efficacy of lung cancer in animals.Nanotheranostics · 2018Article
- Theranostic Probes for Targeting Tumor Microenvironment: An Overview.International journal of molecular sciences · 2017Review
- Imaging the Tumor Microenvironment.Advances in experimental medicine and biology · 2017Review
- Heparin-Regulated Prodrug-Type Macromolecular Theranostic Systems for Cancer Therapy.Nanotheranostics · 2017Review
- Mixed Nanosized Polymeric Micelles as Promoter of Doxorubicin and miRNA-34a Co-Delivery Triggered by Dual Stimuli in Tumor Tissue.Small (Weinheim an der Bergstrasse, Germany) · 2016Article
- Biosynthetic Polymers as Functional Materials.Macromolecules · 2016Review
- Receptor-Mediated Drug Delivery Systems Targeting to Glioma.Nanomaterials (Basel, Switzerland) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-associated proteases (TAPs) have been intensively studied because of their critical roles in cancer development. As a case in point, expression of matrix metalloproteases (MMP) is significantly up-regulated in tumorigenesis, invasion, and metastasis among a majority of cancers. Here we present a prodrug-type, MMP-2-responsive nanoprobe system with high efficiency and low toxicity for detecting MMP-2-overexpressed tumors. The nanoprobe system is featured by its self-assembled fabrication and FRET effect. This prodrug-type nanoprobe is selectively activated by MMP-2, and thus useful for detection of the MMP-2-overexpressed cells and tumors. The nanoprobe system works successfully in various animal tumor models, including human fibrosarcoma and subcutaneous glioma xenograft. Furthermore, in order to overcome the blood brain barrier (BBB) and achieve brain tumor targeting, a transferrin-receptor targeting peptide (T7 peptide) is strategically incorporated into the nanoprobe. The T7-functionalized nanoprobe is capable of detecting the orthotopic brain tumor, with clear, real-time in vivo imaging. This method is promising for in vivo detection of brain tumor, and real-time monitor of a TAP (i.e., MMP-2).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.